Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Trial Parameters
Brief Summary
Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor patients.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Able to understand and willing to sign written informed consent * Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx) * Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care * Informed consent no later than four weeks after start of first-line palliative systemic treatment. For patients receiving "best supportive care only": no later than six weeks after diagnosis/recurrence or metastatic disease Exclusion Criteria: none